As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
Teva’s Fluoxetine capsules are the AB-rated generic equivalent of Eli Lilly’s Sarafem Pulvules, and are indicated for the treatment of premenstrual dysphoric disorder.